Shots:

• The P-lll COVE study involves the assessing of mRNA-1273 (100 µg dose level) in 30-000 patients with COVID-19 in the ratio of (1:1) aged > 18 yrs. in the US
• The study met the statistical criteria pre-specified in the study protocol for efficacy- with a vaccine efficacy of 94.5% in the first interim analysis of the P-III COVE study. The first interim analysis included 95 participants with confirmed cases of COVID-19
• Moderna plans to submit a EUA with US FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of >2mos.

 ­ Ref: Businesswire | Image: Moderna